This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2014 May 22;370(21):2043-7.

doi: 10.1056/NEJMe1403619. Epub 2014 May 4.

Therapy of hepatitis C--back to the future

T Jake Liang¹, Marc G Ghany

Affiliations

PMID: 24795199
PMCID: PMC6324541
DOI: 10.1056/NEJMe1403619

Editorial

Therapy of hepatitis C--back to the future

T Jake Liang et al. N Engl J Med. 2014.

. 2014 May 22;370(21):2043-7.

doi: 10.1056/NEJMe1403619. Epub 2014 May 4.

Authors

T Jake Liang¹, Marc G Ghany

Affiliation

¹ From the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.

PMID: 24795199
PMCID: PMC6324541
DOI: 10.1056/NEJMe1403619

No abstract available

PubMed Disclaimer

Comment on

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. Poordad F, et al. N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/NEJMoa1402869. Epub 2014 Apr 11. N Engl J Med. 2014. PMID: 24725237 Clinical Trial.
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study. Ferenci P, et al. N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4. N Engl J Med. 2014. PMID: 24795200 Clinical Trial.

Similar articles

HCV Resistance Profile Evolution in a GT1b, DAA-Naive Patient Before, On, and After Failing Triple DAA Therapy.
Knops E, Schübel N, Heger E, Neumann-Fraune M, Kaiser R, Inden S, Kalaghatgi P, Sierra S. Knops E, et al. Clin Gastroenterol Hepatol. 2017 Feb;15(2):307-309. doi: 10.1016/j.cgh.2016.09.139. Epub 2016 Sep 23. Clin Gastroenterol Hepatol. 2017. PMID: 27670383 No abstract available.
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS, Xie W, Pilot-Matias T, Liossis G, Larsen L, Khatri A, Podsadecki T, Bernstein B. Kowdley KV, et al. N Engl J Med. 2014 Jan 16;370(3):222-32. doi: 10.1056/NEJMoa1306227. N Engl J Med. 2014. PMID: 24428468 Clinical Trial.
Viral hepatitis: new hepatitis C therapies-a medical pick and mix.
Ray K. Ray K. Nat Rev Gastroenterol Hepatol. 2014 Jun;11(6):329. doi: 10.1038/nrgastro.2014.64. Epub 2014 Apr 29. Nat Rev Gastroenterol Hepatol. 2014. PMID: 24776807 No abstract available.
Treatment of hepatitis C virus genotype 4 in the DAA era.
Di Biagio A, Taramasso L, Cenderello G. Di Biagio A, et al. Virol J. 2018 Nov 22;15(1):180. doi: 10.1186/s12985-018-1094-4. Virol J. 2018. PMID: 30466446 Free PMC article. Review.
Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
Deeks ED. Deeks ED. Drugs. 2015 Jun;75(9):1027-38. doi: 10.1007/s40265-015-0412-z. Drugs. 2015. PMID: 26059288 Review.

See all similar articles

Cited by

Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019.
Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Téllez MJ, Domínguez L, Domingo P, Navarro J, Santos J, Iribarren JA, Morano L, Artero A, Moreno J, Rivero-Román A, Santos I, Giner L, Armiñanzas C, Montero M, Manzardo C, Cifuentes C, García C, Galindo MJ, Ferrero OL, Sanz J, de la Fuente B, Rodríguez C, Gaspar G, Pérez L, Losa JE, Force L, Veloso S, Martínez-Alfaro E, Jarrín I, De Miguel M, González Garcia J; GeSIDA 8514 Study Group. Fanciulli C, et al. HIV Med. 2022 Aug;23(7):705-716. doi: 10.1111/hiv.13229. Epub 2022 Jan 17. HIV Med. 2022. PMID: 35037379 Free PMC article.
HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients.
Brochado-Kith Ó, Martínez I, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A, Ángeles Jiménez-Sousa M, Resino S. Brochado-Kith Ó, et al. Front Immunol. 2021 Aug 23;12:723196. doi: 10.3389/fimmu.2021.723196. eCollection 2021. Front Immunol. 2021. PMID: 34497613 Free PMC article.
Update on the management and treatment of viral hepatitis.
Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Almeida PH, et al. World J Gastroenterol. 2021 Jun 21;27(23):3249-3261. doi: 10.3748/wjg.v27.i23.3249. World J Gastroenterol. 2021. PMID: 34163109 Free PMC article. Review.
HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients.
Brochado Ó, Martínez I, Berenguer J, Medrano L, González-García J, Jiménez-Sousa MÁ, Carrero A, Hontañón V, Navarro J, Guardiola JM, Fernández-Rodríguez A, Resino S; GESIDA Study Group. Brochado Ó, et al. J Biomed Sci. 2021 Mar 30;28(1):23. doi: 10.1186/s12929-021-00718-6. J Biomed Sci. 2021. PMID: 33785040 Free PMC article.
The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence.
Ghany MG, Lok ASF, Dienstag JL, Feinstone SM, Hoofnagle JH, Jake Liang T, Seeff LB, Cohen DE, Bezerra JA, Chung RT. Ghany MG, et al. Hepatology. 2021 Nov;74(5):2813-2823. doi: 10.1002/hep.31830. Epub 2021 Oct 5. Hepatology. 2021. PMID: 33784424 Free PMC article.

See all "Cited by" articles

References

1. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013;368:1907–17. - PMC - PubMed
1. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983–92. - PubMed
1. Poordad F, Hezode C, Trinh R, et al. ABT-450/r–ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973–82. - PubMed
1. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993–2001. - PubMed
1. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370: 1889–98. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations